The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $19.53

Today's change+0.12 +0.62%
Updated February 11 4:00 PM EST. Delayed by at least 15 minutes.
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $19.53

Today's change+0.12 +0.62%
Updated February 11 4:00 PM EST. Delayed by at least 15 minutes.

Meridian Bioscience Inc up (U.S.)$0.12

Meridian Bioscience Inc closed up Thursday by (U.S.)$0.12 or 0.62% to (U.S.)$19.53. Over the last five days, shares have gained 4.38%, but are down 4.82% for the last year to date. Shares have outperformed the S&P 500 by 15.57% during the last year.

Key company metrics

  • Open(U.S.) $19.08
  • Previous close(U.S.) $19.41
  • High(U.S.) $19.73
  • Low(U.S.) $18.72
  • Bid / Ask-- / --
  • YTD % change-4.82%
  • Volume251,181
  • Average volume (10-day)302,926
  • Average volume (1-month)291,390
  • Average volume (3-month)242,971
  • 52-week range(U.S.) $16.60 to (U.S.) $21.23
  • Beta1.16
  • Trailing P/E22.52×
  • P/E 1 year forward21.84×
  • Forward PEG1.37×
  • Indicated annual dividend(U.S.) $0.80
  • Dividend yield4.10%
  • Trailing EPS(U.S.) $0.87
Updated February 11 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.83%

Based on its net profit margin of 18.83%, Meridian Bioscience Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.81%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue47485248
Total other revenue--------
Total revenue47485248
Gross profit30303329
Total cost of revenue17181919
Total operating expense34343635
Selling / general / administrative14131313
Research & development3333
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income13141613
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax13141612
Income after tax89108
Income tax, total5554
Net income89108
Total adjustments to net income--------
Net income before extra. items89108
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items89108
Inc. avail. to common incl. extra. items89108
Diluted net income89108
Dilution adjustment--------
Diluted weighted average shares42424242
Diluted EPS excluding extraordinary itemsvalue per share0.200.220.240.19
Dividends per sharevalue per share0.200.200.200.20
Diluted normalized EPSvalue per share0.200.220.240.19